Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri M, Wrabel E, Williams A, Parsons H, Poorvu PD, Partridge A, Abravanel DL, Poorvu N, LeStage B, Sicinski P, Tolaney SM, Wagle N, Tayob N, Shapiro GI.

Open source

DOI: 10.1158/1078-0432.ccr-26-0721
Published: 2026-07-13
Container: Clin Cancer Res
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0721,
  title = {Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.},
  author = {Waks AG and  Segui E and  Li T and  Lipsyc-Sharf M and  Kallfelz E and  DiLullo M and  Patel A and  Rahman T and  Junkins K and  Rahee H and  Frey AM and  Kelly E and  Stalteri M and  Wrabel E and  Williams A and  Parsons H and  Poorvu PD and  Partridge A and  Abravanel DL and  Poorvu N and  LeStage B and  Sicinski P and  Tolaney SM and  Wagle N and  Tayob N and  Shapiro GI.},
  year = {2026},
  journal = {Clin Cancer Res},
  doi = {10.1158/1078-0432.ccr-26-0721},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0721}
}

RIS

TY  - JOUR
TI  - Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.
AU  - Waks AG
AU  -  Segui E
AU  -  Li T
AU  -  Lipsyc-Sharf M
AU  -  Kallfelz E
AU  -  DiLullo M
AU  -  Patel A
AU  -  Rahman T
AU  -  Junkins K
AU  -  Rahee H
AU  -  Frey AM
AU  -  Kelly E
AU  -  Stalteri M
AU  -  Wrabel E
AU  -  Williams A
AU  -  Parsons H
AU  -  Poorvu PD
AU  -  Partridge A
AU  -  Abravanel DL
AU  -  Poorvu N
AU  -  LeStage B
AU  -  Sicinski P
AU  -  Tolaney SM
AU  -  Wagle N
AU  -  Tayob N
AU  -  Shapiro GI.
PY  - 2026
JO  - Clin Cancer Res
DO  - 10.1158/1078-0432.ccr-26-0721
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0721
ER  -

APA

AG, W., E, S., T, L., M, L., E, K., M, D., A, P., T, R., K, J., H, R., AM, F., E, K., M, S., E, W., A, W., H, P., PD, P., A, P., DL, A., N, P., B, L., P, S., SM, T., N, W., N, T., & GI., S. (2026). Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-26-0721

Source records

europe-pmc · retrieved 2026-09-27T06:23:57.659Z